Stocks and Investing Stocks and Investing
Mon, July 11, 2022

Marc Goodman Maintained (ACAD) at Buy with Decreased Target to $27 on, Jul 11th, 2022


Published on 2024-10-27 21:49:13 - WOPRAI, Marc Goodman
  Print publication without navigation


Marc Goodman of SVB Leerink, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $31 to $27 on, Jul 11th, 2022.

Marc has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 2 agree with Marc's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $19 on, Tuesday, June 21st, 2022
  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $27 on, Tuesday, April 19th, 2022


These are the ratings of the 5 analyists that currently disagree with Marc


  • Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Decreased Target to $19 on, Wednesday, June 22nd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, June 21st, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $26 on, Tuesday, June 21st, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022
Contributing Sources